Effectiveness of tenofovir disoproxil fumarate therapy in chronic hepatitis B patients
Lamivudine and entecavir have been widely used in chronic hepatitis B (CHB) patients with cirrhosis to reduce hepatic events and death. However, the effectiveness of tenofovir disoproxil fumarate (TDF) therapy is still unclear. The study “Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis” assessed the impact of TDF treatment on the risk of hepatocellular carcinoma (HCC), hepatic decompensation and death by comparing the outcomes of TDF-treated and untreated CHB patients with cirrhosis. Among patients with cirrhosis, TDF treatment reduces risks of hepatic decompensation, HCC and death at 5 years. (Aliment Pharmacol Ther. 2019 Nov;50(9):1037-1048. doi: 10.1111/apt.15499. Epub 2019 Sep 16.)
Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Grace Wong in the Department of Medicine & Therapeutics, CUHK. Prof Wong’s research focuses on Non-invasive assessment of liver fibrosis, hepatocellular carcinoma, and chronic viral hepatitis, contrast-enhanced ultrasonography of liver.
Read full article: https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15499